Home » Topics » Regulatory » EMA

EMA
RSS

EMA committee supports approval of Eisai's Kisplyx

July 25, 2016

EMA's CHMP grants positive opinion to Cabometyx in RCC

July 25, 2016

EMA committee recommends approval of Onivyde in E.U.

July 25, 2016

EMA proposes changes to guidance on first-in-human trials

July 22, 2016

EMA grants orphan drug designation to XOMA-358

July 21, 2016

Cynapsus Therapeutics reaches agreement with the EMA for APL-130277 development

July 20, 2016

The EMA classifies AXAL as advanced therapy medicinal product

July 19, 2016

Cladribine tablet MAA accepted for review by EMA

July 18, 2016

EMA accepts for review MAA for adalimumab biosimilar SB-5

July 18, 2016

EMA committee recommends orphan drug designation for Akari's Coversin

July 13, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...